IRD Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

15 days ago - By: Opus Genetics, Inc.

Opus Genetics to Participate in Upcoming Investment Conferences

23 days ago - By: Zacks Investment Research - Mentions: IMTX

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates

23 days ago - By: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

a month ago - By: Benzinga - Mentions: CDXS WORX SINT PPBT ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Zacks Investment Research - Mentions: ZYME

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Opus Genetics, Inc.

Opus Genetics Announces $23 Million Registered Direct Offering

3 months ago - By: Zacks Investment Research - Mentions: SBH BNL

The Under $20 Breakout Trio Investors Shouldn't Ignore

a month ago - By: Benzinga - Mentions: CERS OPRX WORX CMND ...

12 Health Care Stocks Moving In Thursday's After-Market Session

a month ago - By: Zacks Investment Research - Mentions: ALVO

Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for

a month ago - By: Zacks Investment Research - Mentions: FTRE

Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates

a month ago - By: Zacks Investment Research - Mentions: AMGN

Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates

a month ago - By: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Zacks Investment Research - Mentions: CERT

Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2 months ago - By: Opus Genetics, Inc.

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

2 months ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice

2 months ago - By: Opus Genetics, Inc.

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

3 months ago - By: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Opus Genetics, Inc.

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

3 months ago - By: Opus Genetics, Inc.

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

4 months ago - By: Zacks Investment Research - Mentions: HQY

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

4 months ago - By: Zacks Investment Research - Mentions: GLUE

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Opus Genetics, Inc.

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

5 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

6 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

7 months ago - By: Zacks Investment Research - Mentions: VTGN

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

7 months ago - By: Zacks Investment Research - Mentions: BLUE

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: HUMA

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

7 months ago - By: Opus Genetics, Inc.

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

7 months ago - By: Zacks Investment Research - Mentions: PRME

OPUS GENETICS INC (IRD) Stock News

IRD Latest News, Press Relases and Analysis

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

12 Health Care Stocks Moving In Friday's After-Market Session

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

Opus Genetics Announces $23 Million Registered Direct Offering

The Under $20 Breakout Trio Investors Shouldn't Ignore

12 Health Care Stocks Moving In Thursday's After-Market Session

Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for

Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates

Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates